A novel biosignature to assess residual risk in ductal carcinoma in situ (DCIS) patients after standard treatment.

Authors

null

Troy Bremer

PreludeDx, Laguna Hills, CA

Troy Bremer , Chirag Shah , Rakesh Patel , Charlotta Wadsten , Christy Kesslering , Steven Shivers , Pat W. Whitworth , Fredrik Warnberg , Frank Vicini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Citation

J Clin Oncol 38: 2020 (suppl; abstr 548)

DOI

10.1200/JCO.2020.38.15_suppl.548

Abstract #

548

Poster Bd #

40

Abstract Disclosures

Similar Posters